Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Dumortier

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Seminars in Oncology|February 1, 1996
Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safetyG Catimel, M Spielmann, V Dieras, et al.
British Journal of Cancer|October 29, 2002
A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patientsT Bachelot, F Gomez, P Biron, et al.
Cancer Chemotherapy and Pharmacology|March 6, 1998
Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumorsB Tranchand, G Catimel, C Lucas, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Seminars in Oncology|February 1, 1996
Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safetyG Catimel, M Spielmann, V Dieras, et al.
British Journal of Cancer|October 29, 2002
A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patientsT Bachelot, F Gomez, P Biron, et al.
Cancer Chemotherapy and Pharmacology|March 6, 1998
Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumorsB Tranchand, G Catimel, C Lucas, et al.
Pageof 2